Invicta Diagnostic
- Market cap
- ₹ 75 Cr.
- P/E
- 18.3x
- P/B
- 1.63x
- 52-week range
- 58.1 – 105
- ROE
- 14%
- ROCE
- 19.4%
- Debt / equity
- 0.07
- Sector
- Healthcare Services
- Industry
- Healthcare Service Provider
- Listed on
- NSE SME
About
Invicta Diagnostic Limited is engaged in the diagnostic chain offering comprehensive radiology and pathology solutions. It offers a one-stop solution for pathology and radiology testing services such as imaging (including radiology), pathology/clinical laboratory and tele-radiology to customers under the brand name PC Diagnostics through its operational network, which consists of eight diagnostic centers and one centralized laboratory across Mumbai Metropolitan Region in the state of Maharashtra. Its test menu includes pathology tests ranging from basic biochemistry and clinical pathology which are performed at its own centers to cytogenetics and high-end molecular diagnostic tests which are outsourced to larger reference laboratories, and radiology tests ranging from basic echocardiograms, X-rays and ultrasounds to advanced radiology tests including computerized tomography (CT) scans, magnetic resonance imaging (MRI) scans and advanced positron emission tomography CT.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Healthcare Service Provider: 36 companies →Invicta Diagnostic against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)18.3 against a typical 21: cheaper than most peers (1st = cheapest).15th of 34
- Share price, 3 months−3.4% against a typical −5.5%.13th of 33
- Size₹ 75.4 Cr. market value against a typical ₹ 83 Cr. (1st = largest).18th of 34
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 29 Jul 2026 | Other business matters | 1. To consider and take on record the resignation of Mr. Rohit Prakash Srivastava (DIN: 01432112) from the office of Whole-time Director and Director of the Company and to consider waiver of the notice period.2. To consider and take on record the resignation of Ms. Konica Rohit Srivastava from the office of Manager (Key Managerial Personnel) of the Company and to consider waiver of the notice period.3. To consider and approve the appointment of Mr. Sanket Vinod Jain, DIN-08299039 Director of the Company, as the Managing Director of the Company, subject to the approval(s), if any, as may be required under the Companies Act, 2013, the rules made thereunder and other applicable laws4. To consider and approve the sale/disposal of the Company's entire investment representing 50% stake in MSCRIBEIT INFOTECH LLP, an associate LLP of the Company, (which currently holds NIL assets, NIL liabilities, and has no operational business activities) to a non-related party, together with matters incidental thereto.5. To transact such other business as may be considered necessary with the permission of the Chair |
| 18 May 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 25 Mar 2026 | Other business matters | To consider other business matters I. Appointment of Mr. Rohit Prakash Srivastava (DIN: 01432112) as Additional Director (Whole Time Director- Finance) of the Company. II. Approval of Material Related Party Transactions in the ordinary course of business and on arm s length basis, pursuant Section 188 of the Companies Act, 2013, subject to approval of shareholders in ensuing Extra Ordinary General Meeting III. Approval of Related Party Transactions , in the ordinary course of business and on arm s length basis, pursuant Section 188 of the Companies Act, 2013, subject to approval of shareholders in ensuing Extra Ordinary General Meeting IV. Approval for Change, Deviation and Variation in the Objects of Utilisation of the Initial Public Offering ( IPO ) Proceeds and extension of time limit for utilisation of the IPO Proceeds subject to approval of shareholders in ensuing Extra Ordinary General Meeting V. To fix Day, Date, Time of ensuing Extra Ordinary General Meeting |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2025 | Mar 2026 |
|---|---|---|
| Sales | 17 | 15 |
| Expenses | 10 | 12 |
| Operating Profit | 7 | 3 |
| OPM % | 39.9% | 19.4% |
| Other Income | 0 | 1 |
| Interest | 0 | 0 |
| Depreciation | 1 | 2 |
| Profit before tax | 5 | 2 |
| Tax % | 24.7% | 50% |
| Net Profit | 4 | 1 |
| EPS in Rs | 4.32 | 0.72 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 63%
- TTM
- 7%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 37%
- TTM
- −9%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 21%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Invicta Diagnostic | ₹ 64.50 | ₹ 75 Cr. | 18.3x | 1.6x | 14% | — |
| Apollo Hospitals Enterprise | ₹ 7,731.95 | ₹ 1,11,174 Cr. | 57x | 11.8x | — | 8.1% |
| Max Healthcare Institute | ₹ 817.00 | ₹ 79,519 Cr. | 56.8x | 7.8x | — | 16.7% |
| Aster DM Healthcare | ₹ 651.00 | ₹ 56,817 Cr. | 84.6x | 7.7x | — | 7.4% |
| Fortis Healthcare | ₹ 720.00 | ₹ 54,357 Cr. | 54.1x | 5.8x | — | 11.3% |
| Global Health | ₹ 1,165.00 | ₹ 31,449 Cr. | 63.3x | 8.9x | — | 11.8% |
Management
- Rohit Prakash Srivastava
- Chief Financial Officer
- Soniya Nilesh Mahajan
- Company Secretary, Compliance Officer
- Konica Rohit Srivastava
- Manager
Prices are delayed and for information only. Nothing on this page is investment advice.